Skip to main content
. 2022 Sep 5;14(17):4340. doi: 10.3390/cancers14174340

Figure 3.

Figure 3

Overall Survival curves according to considered PO-SACT modalities: panel (a): oxaliplatin versus irinotecan; panel (b): 5-fluorouracil versus capecitabine; panel (c): cetuximab/panitumumab versus bevacizumab. PO-SACT: pre-operative systemic anticancer therapy.